サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1609961

パラセタモール静脈注射の市場規模、シェア、動向分析レポート：適応症別、用途別、最終用途別、地域別、セグメント別予測、2025年～2030年

Paracetamol IV Market Size, Share & Trends Analysis Report By Indication (Pain, Pyrexia), By Application (Surgical, Non-surgical), By End Use (Hospitals, Clinics), By Region (North America, Asia Pacific), And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
パラセタモール静脈注射の市場規模、シェア、動向分析レポート：適応症別、用途別、最終用途別、地域別、セグメント別予測、2025年～2030年
出版日: 2024年11月11日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

パラセタモール静脈注射市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のパラセタモール静脈注射市場規模は2025年から2030年にかけてCAGR 3.43%で拡大し、2030年には9億9,423万米ドルに達すると推定されています。

疼痛管理を必要とする慢性疾患の有病率の上昇は、予測期間中の業界の成長を促進すると予想されています。疼痛管理のためのオピオイド依存を軽減するためにアセトアミノフェンの使用量が増加していることが、パラセタモール静脈注射の需要の伸びを加速すると予測されています。パラセタモール静脈注射剤は安定したアセトアミノフェン製剤で、軽度から中等度の疼痛管理を目的としています。パラセタモールは血小板の機能を阻害しないため、消化性潰瘍や喘息の既往歴のある患者の治療に他の非ステロイド性抗炎症薬よりも多く使用されています。

術後疼痛を訴える患者の増加により、副作用の少ない医薬品や製品の需要が高まると予想されます。International Journal of Surgery誌に掲載された論文によると、2022年3月、米国では患者の77％～83％、タイでは患者の80％、スウェーデンでは患者の76％、ドイツでは患者の29.5％が術後痛が重度から中等度であると報告しています。静脈内パラセタモールは、急性術後痛の治療や、整形外科、歯科、婦人科などの手術中の使用を目的としています。手術件数の増加や術後痛を経験する患者の増加により、今後数年間は高い製品需要が見込まれます。しかし、複数のジェネリック製品が入手可能であることが、予測期間中の業界の妨げになると予想されます。

例えば、2020年12月、Sandoz International GmbHは米国でアセトアミノフェン注射剤のジェネリック医薬品を発売しました。この製品は、小児患者のオピオイド鎮痛薬との併用による軽度から中等度の治療用に、濃度10mg/mL、100mLバイアルで発売される予定です。世界の業界で事業を展開する主要企業は、事業拡大や他社に対する競争優位性を獲得するために、さまざまな戦略的イニシアチブをとっています。例えば、2021年12月、Leucadia Pharmaceuticals社は、Mallinckrodt Pharmaceuticals社が製造するアセトアミノフェン注射剤に対応するFDA承認のジェネリックであるアセトアミノフェン注射剤を発売、発表しました。

パラセタモール静脈注射市場レポートハイライト

  • 用途別では、発熱セグメントが2025年から2030年にかけて最も速いCAGRを記録すると推定されます。
  • 同分野の成長は、パラセタモールの静脈内投与による速効性と有効性に起因します。
  • 2024年には、術後痛の治療や発熱の迅速な緩和のためにパラセタモール静脈注射の使用量が増加したため、外科用途分野が最大の売上シェアを占めました。
  • 北米は、疼痛管理のためのオピオイドへの経済的依存を軽減するための高い製品使用量により、2024年に世界の業界を支配しました。
  • 企業は、業界における競争力を維持するために、提携、パートナーシップ、新製品の発売、戦略的イニシアティブなどの戦略を採用し、地理的拡大に注力しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 パラセタモール静脈注射市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場 促進要因分析
    • 市場抑制要因分析
  • パラセタモール静脈注射市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 パラセタモール静脈注射市場： 適応症の推定・動向分析

  • セグメントダッシュボード
  • パラセタモール静脈注射市場：適応症変動分析
  • パラセタモール静脈注射市場適応症別展望
  • 2018年から2030年までの市場規模と予測および動向分析
  • 疼痛
  • 発熱

第5章 パラセタモール静脈注射市場： 用途の推定・動向分析

  • セグメントダッシュボード
  • パラセタモール静脈注射市場：用途変動分析
  • パラセタモール静脈注射市場- 用途別展望
  • 2018年から2030年までの市場規模と予測および動向分析
  • 外科手術
  • 非外科手術

第6章 パラセタモール静脈注射市場：最終用途の推定・動向分析

  • セグメントダッシュボード
  • パラセタモール静脈注射市場：最終用途変動分析
  • 最終用途別パラセタモール静脈注射市場展望
  • 2018年から2030年までの市場規模と予測および動向分析
  • 病院
  • クリニック
  • その他

第7章 パラセタモール静脈注射市場：地域の推定・動向分析

  • 地域ダッシュボード
  • 市場規模と予測動向分析、2018年から2030年
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 市場参入企業の分類
  • 主要市場参入企業による最近の動向と影響分析
  • 企業市場シェア分析、2024年
  • 主要企業プロファイル
    • Mallinckrodt（Mallinckrodt Pharmaceuticals）
    • Cipla Inc.
    • Lupin
    • Dr. Reddy's Laboratories Ltd.
    • Aurobindo Pharma
    • Sun Pharmaceutical Industries Ltd.
    • Novartis AG
    • Pfizer, Inc.
    • Abbott
    • Sanofi
    • Bristol-Myers Squibb Company
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Regulatory Framework
  • Table 4 Global Paracetamol IV Market, By Region, 2018 - 2030 (USD Million)
  • Table 5 Global Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 6 Global Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 7 Global Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 8 North America Paracetamol IV Market, By Country, 2018 - 2030 (USD Million)
  • Table 9 North America Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 10 North America Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 11 North America Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 12 U.S. Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 13 U.S. Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 14 U.S. Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 15 Canada Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 16 Canada Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 17 Canada Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 18 Mexico Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 19 Mexico Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 20 Mexico Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 21 Europe Paracetamol IV Market, By Country, 2018 - 2030 (USD Million)
  • Table 22 Europe Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 23 Europe Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 24 Europe Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 25 U.K. Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 26 U.K. Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 27 U.K. Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 28 Germany Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 29 Germany Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 30 Germany America Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 31 France Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 32 France Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 33 France Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 34 Spain Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 35 Spain Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 36 Spain Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 37 Italy Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 38 Italy Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 39 Italy Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 40 Denmark Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 41 Denmark Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 42 Denmark Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 43 Sweden Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 44 Sweden Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 45 Sweden Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 46 Norway Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 47 Norway Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 48 Norway Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Paracetamol IV Market, By Country, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 52 Asia Pacific Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 53 China Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 54 China Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 55 China Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 56 Japan Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 57 Japan Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 58 Japan Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 59 India Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 60 India Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 61 India Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 62 South Korea Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 63 South Korea Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 64 South Korea Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 65 Australia Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 66 Australia Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 67 Australia Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 68 Thailand Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 69 Thailand Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 70 Thailand Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 71 Latin America Paracetamol IV Market, By Country, 2018 - 2030 (USD Million)
  • Table 72 Latin America Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 73 Latin America Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 74 Latin America Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 75 Brazil Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 76 Brazil Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 77 Brazil Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 78 Argentina Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 79 Argentina Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 80 Argentina Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 81 MEA Paracetamol IV Market, By Country, 2018 - 2030 (USD Million)
  • Table 82 MEA Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 83 MEA Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 84 MEA Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 85 South Africa Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 86 South Africa Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 87 South Africa Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 88 UAE Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 89 UAE Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 90 UAE Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 91 Saudi Arabia Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 92 Saudi Arabia Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 93 Saudi Arabia Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Paracetamol IV Market, By Indication, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Paracetamol IV Market, By Application, 2018 - 2030 (USD Million)
  • Table 96 Kuwait Paracetamol IV Market, By End-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research approaches
  • Fig. 2 Value chain-based sizing & forecasting
  • Fig. 3 Market formulation & validation
  • Fig. 4 Paracetamol IV market segmentation
  • Fig. 5 Market driver analysis (current & future impact)
  • Fig. 6 Market restraint analysis (current & future impact)
  • Fig. 7 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 8 Porter's five forces analysis
  • Fig. 9 Global Paracetamol IV market: Indication outlook and key takeaways
  • Fig. 10 Global Paracetamol IV market: Indication movement analysis
  • Fig. 11 Pain market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 12 Pyrexia (Fever) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 13 Global Paracetamol IV market: Application type outlook and key takeaways
  • Fig. 14 Global Paracetamol IV market: Application type movement analysis
  • Fig. 15 Surgical market estimates and forecast, 2018 - 2030
  • Fig. 16 Non-Surgical market estimates and forecast, 2018 - 2030
  • Fig. 17 Global Paracetamol IV market: End use outlook and key takeaways
  • Fig. 18 Global Paracetamol IV market: End use movement analysis
  • Fig. 19 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 North America Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Canada Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Mexico Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Europe Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 UK Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Germany Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 France Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Italy Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Spain Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Denmark Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Sweden Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Norway Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Asia Pacific Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Japan Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 China Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 India Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Australia Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Thailand Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 South Korea Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Latin America Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Brazil Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Argentina Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 MEA Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 South Africa Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Saudi Arabia Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 UAE Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Kuwait Paracetamol IV market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 List of key emerging company's/disruptors/innovators
目次
Product Code: GVR-4-68039-965-3

Paracetamol IV Market Growth & Trends:

The global paracetamol IV market size is estimated to reach USD 994.23 million by 2030, expanding at a CAGR of 3.43% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of chronic disorders that requires pain management is expected to facilitate the growth of the industry during the forecast period. The enhanced usage of acetaminophen to reduce the dependence on opioids for pain management is projected to accelerate the growth in demand for paracetamol IV. The IV paracetamol is a stable acetaminophen form and is intended for mild to moderate pain management. It is used over other NSAIDs to treat patients with a history of peptic ulcers and asthma, as it lacks interference with the function of platelets.

Rising cases of patients reporting postoperative pain are expected to propel the demand for drugs and products with fewer side effects. As per the article published in the International Journal of Surgery, in March 2022, 77% - 83% of patients in the U.S., 80% of patients in Thailand, 76% of patients in Sweden, and 29.5% of patients in Germany reported severe to moderate postoperative pain. The IV paracetamol is intended for usage in the treatment of acute postoperative pain and during the surgeries, such as orthopedic, dental, and gynecological. A rise in the number of surgeries performed and patients experiencing post-operative pain is expected to create a high product demand in the years to come. However, the availability of multiple generic products is expected to hinder the industry during the forecast period.

For instance, in December 2020, Sandoz International GmbH launched a generic acetaminophen injection in the U.S. The product will be available in 10 mg/mL concentration, in a 100 mL vial for the treatment of mild to moderate in conjunction with opioid analgesics for pediatric patients. Key players operating in the global industry are following various strategic initiatives for business expansion and to gain a competitive edge over others. For instance, in December 2021, Leucadia Pharmaceuticals launched and announced the availability of a generic acetaminophen injection, which is an FDA-approved generic that corresponds to the acetaminophen injection manufactured by Mallinckrodt Pharmaceuticals.

Paracetamol IV Market Report Highlights:

  • Based on application, the pyrexia segment is estimated to register the fastest CAGR from 2025 to 2030.
  • The growth of the segment is attributed to the rapid action & effectiveness of paracetamol being administered intravenously.
  • The surgical application segment held the largest revenue share in 2024 due to the increased usage of paracetamol IV for the treatment of post-operative pain and rapid relief from fever.
  • North America dominated the global industry in 2024 owing to high product usage for reducing the dependence of the economy on opioids for the management of pain.
  • Companies are focusing on geographical expansion by adopting strategies, such as collaborations, partnerships, new product launches, and strategic initiatives to maintain a competitive position in the industry.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Application
    • 1.2.3. End Use
    • 1.2.4. Regional Scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Paracetamol IV Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising cases of postoperative pain
      • 3.2.1.2. Increasing prevalence of chronic disorders
      • 3.2.1.3. Increasing use of intravenous paracetamol in combination with NSAIDs and narcotics
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Overdose of paracetamol IV
      • 3.2.2.2. Availability of generic products
  • 3.3. Paracetamol IV Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Paracetamol IV Market: Indication Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Paracetamol IV Market: Indication Movement Analysis
  • 4.3. Paracetamol IV Market by Indication Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Pain
    • 4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Pyrexia (Fever)
    • 4.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Paracetamol IV Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Paracetamol IV Market: Application Movement Analysis
  • 5.3. Paracetamol IV Market by Application Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Surgical
    • 5.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Non-surgical
    • 5.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Paracetamol IV Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Paracetamol IV Market: End Use Movement Analysis
  • 6.3. Paracetamol IV Market by End Use Outlook (USD Million)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. Hospitals
    • 6.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Clinics
    • 6.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Paracetamol IV Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Dashboard
  • 7.2. Market Size & Forecasts Trend Analysis, 2018 to 2030
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Recent Developments & Impact Analysis by Key Market Participants
  • 8.3. Company Market Share Analysis, 2024
  • 8.4. Key Company Profiles
    • 8.4.1. Mallinckrodt (Mallinckrodt Pharmaceuticals)
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Cipla Inc.
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Lupin
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Dr. Reddy's Laboratories Ltd.
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Aurobindo Pharma
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Sun Pharmaceutical Industries Ltd.
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Novartis AG
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Pfizer, Inc.
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Abbott
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Sanofi
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives
    • 8.4.11. Bristol-Myers Squibb Company
      • 8.4.11.1. Company overview
      • 8.4.11.2. Financial performance
      • 8.4.11.3. Product benchmarking
      • 8.4.11.4. Strategic initiatives